Cord Blood for Autism: What the Research Actually Shows
Cord blood for autism is one of the most-asked questions in cord blood banking — partly because of widely-shared family stories, and partly because of early trials at Duke. The honest scientific picture is more nuanced than the marketing suggests.
The early Duke research
A 2017 phase I trial at Duke University led by Dr. Joanne Kurtzberg gave 25 children with autism a single autologous cord blood infusion and reported improvements in some behavioral measures at six months. The trial was open-label and uncontrolled, so it could only generate hypotheses, not prove cause and effect.
The larger controlled trial
The follow-up phase II trial, published in 2020, was the larger, randomized, placebo-controlled test of the same idea. It enrolled 180 children and did not find a statistically significant improvement in core autism symptoms versus placebo at six months. Subgroup analyses suggested possible benefit for non-verbal children with higher IQs, but those findings were exploratory and need replication.
Where the research stands now
Research continues, but cord blood is not an FDA-approved treatment for autism. Subsequent studies have looked at mesenchymal stem cells from cord tissue, repeat dosing, and specific subpopulations. None of this work has produced evidence sufficient for FDA approval, and major pediatric organizations don't endorse cord blood as autism therapy.
Honest takeaway for banking decisions
- Cord blood is not a proven autism treatment as of 2025
- Future research may change this — banking preserves the option, but doesn't guarantee a benefit
- Be skeptical of any bank that markets autism treatment as a current capability
- If you're considering banking specifically for this reason, talk to a pediatric stem cell researcher before signing